trending Market Intelligence /marketintelligence/en/news-insights/trending/f6kvcabsl_y0bpwcimsizq2 content esgSubNav
In This List

LivaNova medical implant receives US FDA clearance for treating heart condition

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


LivaNova medical implant receives US FDA clearance for treating heart condition

LivaNova PLC said the U.S. Food and Drug Administration granted 510(k) clearance to its medical implant Memo 4D, a semi-rigid ring used for treating a type of heart condition.

The London-based medical device maker said the Memo 4D is a semi-rigid mitral annuloplasty ring to treat mitral regurgitation, a disorder of the heart in which the mitral valve does not close properly when the heart pumps out blood.

Mitral valve annuloplasty is a surgical technique for the repair of leaking mitral valves.